Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases

Background and Aims: The clinical use of azathioprine and 6-mercaptopurine is limited by their delayed onset of action and potential side effects such as myelosuppression and hepatotoxicity. As these drugs specifically target the Vav1/Rac1 signalling pathway in T lamina propria lymphocytes via their...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Crohn's and colitis 2016-10, Vol.10 (10), p.1132-1143
Hauptverfasser:	Atreya, Imke, Diall, Alexandra, Dvorsky, Radovan, Atreya, Raja, Henninger, Christian, Grün, Mathias, Hofmann, Ute, Schaeffeler, Elke, López-Posadas, Rocío, Daehn, Ilse, Zenker, Stefanie, Döbrönti, Michael, Neufert, Clemens, Billmeier, Ulrike, Zundler, Sebastian, Fritz, Gerhard, Schwab, Matthias, Neurath, Markus F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Biomarkers - metabolism Case-Control Studies Designer Drugs - pharmacology Designer Drugs - therapeutic use Drug Design Humans Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology Inflammatory Bowel Diseases - metabolism Intestinal Mucosa - drug effects Intestinal Mucosa - immunology Intestinal Mucosa - metabolism Mercaptopurine - analogs & derivatives Mercaptopurine - pharmacology Mercaptopurine - therapeutic use Proto-Oncogene Proteins c-vav - metabolism rac1 GTP-Binding Protein - metabolism Signal Transduction - drug effects T-Lymphocytes - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!